首页 > 期刊杂志 > 正文

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis.

Berglund M,Thunberg U,Amini RM,Book M,Roos G,Erlanson M,Linderoth J,Dictor M,Jerkeman M,Cavallin-Ståhl E,Sundström C,Rehn-Eriksson S,Backlin C,Hagberg H,Rosenquist R,Enblad G

Abstract

Diffuse large B-cell lymphoma (DLBCL) has been shown to be comprised of at least two prognostic entities, depending on its resemblance to normal germinal center or activated B cells, using global gene expression profiling. Also, the expression patterns of bcl-6, CD10 and IRF-4 (also known as MUM1) have been suggested as alternative means of identifying the germinal- and nongerminal center (activated B-cell like) groups. In the present study, we evaluated by immunohistochemistry the expression patterns of CD10, bcl-6, IRF-4 and bcl-2 in a large material of 161 DLBCL patients. Using two different approaches, patients with germinal center phenotype displayed a significantly better survival than the nongerminal center group. Positive staining for bcl-6 or CD10 predicted for superior survival, while expression of IRF-4 alone showed no association with prognosis. Furthermore, expression of bcl-2 was associated with worse event-free survival and overall survival. In a multivariate analysis, a high international prognostic index score (3-5), non-GC phenotype and bcl-2 were independent adverse prognostic factors. Here we confirm the prognostic importance of determining the germinal- or nongerminal center phenotype in patients with DLBCL.

摘要

full text

我要评论

0条评论